AU4242102A - Use of anti-ctla-4 antibodies - Google Patents

Use of anti-ctla-4 antibodies Download PDF

Info

Publication number
AU4242102A
AU4242102A AU42421/02A AU4242102A AU4242102A AU 4242102 A AU4242102 A AU 4242102A AU 42421/02 A AU42421/02 A AU 42421/02A AU 4242102 A AU4242102 A AU 4242102A AU 4242102 A AU4242102 A AU 4242102A
Authority
AU
Australia
Prior art keywords
cancer
ser
thr
leu
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU42421/02A
Other languages
English (en)
Inventor
Douglas Charles Hanson
Eileen Elliott Mueller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of AU4242102A publication Critical patent/AU4242102A/en
Priority to AU2006203397A priority Critical patent/AU2006203397A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU42421/02A 2001-05-23 2002-05-21 Use of anti-ctla-4 antibodies Abandoned AU4242102A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2006203397A AU2006203397A1 (en) 2001-05-23 2006-08-07 Use of anti-CTLA-4 antibodies

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29304201P 2001-05-23 2001-05-23
US60/293042 2001-05-23

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2006203397A Division AU2006203397A1 (en) 2001-05-23 2006-08-07 Use of anti-CTLA-4 antibodies

Publications (1)

Publication Number Publication Date
AU4242102A true AU4242102A (en) 2002-11-28

Family

ID=23127385

Family Applications (1)

Application Number Title Priority Date Filing Date
AU42421/02A Abandoned AU4242102A (en) 2001-05-23 2002-05-21 Use of anti-ctla-4 antibodies

Country Status (14)

Country Link
US (1) US20030086930A1 (en:Method)
EP (1) EP1262193A1 (en:Method)
JP (1) JP2002371013A (en:Method)
KR (1) KR100531707B1 (en:Method)
CN (1) CN1404876A (en:Method)
AU (1) AU4242102A (en:Method)
CA (1) CA2382443A1 (en:Method)
CZ (1) CZ20021760A3 (en:Method)
HU (1) HUP0201737A2 (en:Method)
IL (1) IL149701A0 (en:Method)
MY (1) MY136095A (en:Method)
PL (1) PL354112A1 (en:Method)
SK (1) SK7242002A3 (en:Method)
ZA (1) ZA200204020B (en:Method)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE05627B1 (et) * 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US7030219B2 (en) 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
US7357928B2 (en) * 2002-04-08 2008-04-15 University Of Louisville Research Foundation, Inc. Method for the diagnosis and prognosis of malignant diseases
CA2481207C (en) * 2002-04-12 2015-06-30 Medarex, Inc. Methods of treatment using ctla-4 antibodies
RS52889B (sr) 2002-09-06 2014-02-28 Amgen Inc Terapijsko humano anti-il-1r1 monoklonsko antitelo
US20040197312A1 (en) * 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
US7465446B2 (en) 2003-05-30 2008-12-16 Medarex, Inc. Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
KR101531400B1 (ko) 2003-06-27 2015-06-26 암젠 프레몬트 인코포레이티드 상피 성장 인자 수용체의 결실 돌연변이체 지향 항체 및 그용도
NZ544911A (en) 2003-07-22 2008-12-24 Schering Ag RG1 antibodies and uses thereof
CA2535859A1 (en) * 2003-08-14 2005-03-03 Dyax Corp. Endotheliase-2 ligands
EP1515505A1 (en) * 2003-09-12 2005-03-16 Siemens Aktiengesellschaft Reachability maintainance of a moving network based on temporary name identifiers
US20050136055A1 (en) * 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
JP2007526455A (ja) * 2004-02-03 2007-09-13 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 癌を特徴付ける、制御する、診断する、および処置するための組成物ならびに方法
JP2007530526A (ja) * 2004-03-26 2007-11-01 ファイザー・プロダクツ・インク 抗ctla−4抗体の使用
US7785591B2 (en) 2004-10-14 2010-08-31 Morphosys Ag Identification and characterization of function-blocking anti-ED-B-fibronectin antibodies
KR20070067702A (ko) * 2004-11-04 2007-06-28 화이자 프로덕츠 인크. 유방암을 치료하기 위한 ctla-4 항체와 아로마타제억제제 병용 요법
TW200719913A (en) 2005-03-08 2007-06-01 Pharmacia & Upjohn Co Llc Anti-madcam antibody compositions
CN101146553A (zh) * 2005-03-23 2008-03-19 辉瑞产品公司 用于治疗癌症的抗-ctla4抗体和吲哚酮组合治疗
AU2006227879A1 (en) * 2005-03-23 2006-09-28 Pfizer Products Inc. Therapy of prostate cancer with CTLA4 antibodies and hormonal therapy
NZ563193A (en) * 2005-05-09 2010-05-28 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
SI2397156T1 (sl) 2005-06-08 2017-06-30 Dana-Farber Cancer Institute, Inc. Metode in sestavki za zdravljenje trdovratnih okužb in raka z inhibiranjem polipeptida za apoptozo 1 (PD-1)
EA200800268A1 (ru) * 2005-07-07 2008-06-30 Коли Фармасьютикал Груп, Инк. КОМБИНИРОВАННАЯ ТЕРАПИЯ АНТИТЕЛОМ ПРОТИВ CTLA-4 И СОДЕРЖАЩИМ CpG-МОТИВ СИНТЕТИЧЕСКИМ ОЛИГОДЕЗОКСИНУКЛЕОТИДОМ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ
US8110194B2 (en) 2005-12-07 2012-02-07 Medarex, Inc. CTLA-4 antibody dosage escalation regimens
EP2007423A2 (en) * 2006-04-05 2008-12-31 Pfizer Products Incorporated Ctla4 antibody combination therapy
WO2009016449A1 (en) * 2007-07-27 2009-02-05 Pfizer Limited Antibody purification process by precipitation
KR101666228B1 (ko) 2007-09-28 2016-10-13 인트렉손 코포레이션 생물치료학적 분자를 발현시키기 위한 치료학적 유전자-스위치 작제물 및 생물반응기, 및 이의 용도
RU2373836C2 (ru) * 2007-12-18 2009-11-27 Федеральное государственное учреждение "Научно-исследовательский институт онкологии имени Н.Н. Петрова Федерального агентства по высокотехнологичной медицинской помощи" Способ оптимизации лечебной тактики при лимфоме ходжкина у детей и подростков
JP2011509299A (ja) * 2008-01-08 2011-03-24 ブリストル−マイヤーズ スクイブ カンパニー 増殖性疾患治療のための、抗ctla−4抗体とチューブリン調節剤との組み合わせ
US8119129B2 (en) 2008-08-01 2012-02-21 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
ES2768990T3 (es) * 2009-07-20 2020-06-24 Bristol Myers Squibb Co Combinación de anticuerpos anti-CTLA4 con gemcitabina para el tratamiento sinérgico de enfermedades proliferativas
RU2421217C2 (ru) * 2009-09-03 2011-06-20 Учреждение Российской академии медицинских наук Гематологический научный центр РАМН (ГНЦ РАМН) Способ дифференцированного лечения диффузных в-крупноклеточных лимфосарком лимфоидных органов взрослых
EP3536708A1 (en) 2011-04-19 2019-09-11 Pfizer Inc Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
ES2572915T3 (es) 2011-06-02 2016-06-03 The University Of Louisville Research Foundation, Inc. Nanopartículas conjugadas a un agente antinucleolina
MX365139B (es) 2012-03-13 2019-05-24 Hoffmann La Roche Uso de una terapia combinada de bevacizumab y paclitaxel en el tratamiento de cáncer de ovario epitelial resistente al platino, carcinoma de las trompas de falopio resistente al platino, o carcinoma peritoneal primario resistente al platino.
MX376234B (es) 2012-05-04 2025-03-07 Pfizer Anticuerpo anti-ctla-4 como modulador inmune.
US8968742B2 (en) * 2012-08-23 2015-03-03 Agensys, Inc. Antibody drug conjugates (ADC) that bind to 158P1D7 proteins
HUE043903T2 (hu) * 2012-12-03 2019-09-30 Bristol Myers Squibb Co Immunmodulációs FC fúziós proteinek rákellenes aktivitásának javítása
JP6649254B2 (ja) 2013-08-08 2020-02-19 サイチューン ファーマ IL−15及びIL−15Rαスシドメインに基づくモジュロカイン
EP3030262B1 (en) 2013-08-08 2019-10-09 Cytune Pharma Combined pharmaceutical composition
KR102338453B1 (ko) * 2013-10-18 2021-12-13 리제너론 파아마슈티컬스, 인크. Vegf 길항제와 항-ctla-4 항체의 조합물을 포함하는 조성물 및 방법
JP6712952B2 (ja) * 2014-03-31 2020-06-24 ザ・ジョンズ・ホプキンス・ユニバーシティー 固形腫瘍悪性病変を処置するための、抗ctla−4抗体および/または抗pd−1抗体と組み合わせた、細菌、細菌産物、および他の免疫調節性実体の使用
WO2015166640A1 (ja) * 2014-05-01 2015-11-05 株式会社アネロファーマ・サイエンス 異種ポリペプチド発現カセット
NZ764826A (en) 2014-05-28 2024-09-27 Memorial Sloan Kettering Cancer Center Anti-gitr antibodies and methods of use thereof
CN105296433B (zh) 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
TR201907471T4 (tr) 2014-08-28 2019-06-21 Halozyme Inc Bir hiyalüronan ayrıştırıcı enzim ve bir bağışıklık kontrol noktası inhibitörüyle kombinasyon terapisi.
US20170248603A1 (en) 2014-10-06 2017-08-31 Dana-Farber Cancer Institute, Inc. Angiopoiten-2 biomarkers predictive of anti-immune checkpoint response
NZ746680A (en) 2014-10-14 2020-07-31 Halozyme Inc Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
PT3240801T (pt) 2014-12-31 2021-02-18 Checkmate Pharmaceuticals Inc Imunoterapia antitumoral combinada
AR103675A1 (es) * 2015-02-13 2017-05-24 Sorrento Therapeutics Inc Anticuerpos anti-ctla4 terapéuticos
CA3020885A1 (en) 2015-05-05 2016-11-10 Mohammad Tariq MALIK Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and mri and/or x-ray contrast agents
AU2016271591A1 (en) * 2015-05-29 2017-12-21 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
US9902772B2 (en) * 2015-07-22 2018-02-27 Sorrento Therapeutics, Inc. Antibody therapeutics that bind LAG3
US11419934B2 (en) 2015-08-18 2022-08-23 Oncotelic Therapeutics, Inc. Use of VDAS to enhance immunomodulating therapies against tumors
TWI717432B (zh) 2015-12-02 2021-02-01 美商艾吉納斯公司 抗體和使用彼之方法
WO2017165742A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
WO2017165778A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in immune oncology treatments
WO2017173334A1 (en) 2016-04-01 2017-10-05 Checkmate Pharmaceuticals, Inc. Fc receptor-mediated drug delivery
EA039322B1 (ru) * 2016-04-15 2022-01-13 Эйдженус Инк. Антитела против ctla-4 и способы их применения
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
JP7198666B2 (ja) * 2016-08-26 2023-01-04 哲治 奥野 微小血管血流低減剤およびその利用
AU2017373944B2 (en) * 2016-12-07 2022-02-03 Agenus Inc. Anti-CTLA-4 antibodies and methods of use thereof
MA50948A (fr) 2016-12-07 2020-10-14 Agenus Inc Anticorps et procédés d'utilisation de ceux-ci
US12129299B2 (en) 2018-02-02 2024-10-29 OncoC4, Inc. Mutant anti-CTLA-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects
US12246031B2 (en) 2018-02-13 2025-03-11 Checkmate Pharmaceuticals, Inc. Compositions and methods for tumor immunotherapy
EP3768721A4 (en) * 2018-03-19 2021-12-29 Wuxi Biologics Ireland Limited. Novel anti-ctla-4 antibody polypeptide
SG11202009647VA (en) 2018-04-09 2020-10-29 Checkmate Pharmaceuticals Packaging oligonucleotides into virus-like particles
EP3820992A2 (en) 2018-07-11 2021-05-19 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
CN110092826B (zh) * 2019-02-28 2022-04-15 天津大学 CTLA-4类似物CFN13及CFN13-Fc基因和蛋白
CN115803343A (zh) * 2020-05-26 2023-03-14 百奥泰生物制药股份有限公司 多特异性抗体及其应用
WO2022010537A1 (en) 2020-07-10 2022-01-13 The Regents Of The University Of Michigan Gas41 inhibitors and methods of use thereof
WO2022086852A2 (en) 2020-10-19 2022-04-28 Dana-Farber Cancer Institute, Inc. Germline biomarkers of clinical response and benefit to immune checkpoint inhibitor therapy
EP4326321A1 (en) 2021-04-20 2024-02-28 Institut Curie Compositions and methods for use in immunotherapy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994362A (en) * 1992-03-11 1999-11-30 Merck & Co., Inc. Method of treatment for prostatic cancer
US5811097A (en) * 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
EE05627B1 (et) * 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
OA11917A (en) * 1998-12-23 2006-04-13 Abgenix Inc Human monoclonal antibodies to ctla-4.
KR100996759B1 (ko) * 1999-08-24 2010-11-25 메다렉스, 인코포레이티드 인간 씨티엘에이-4 항체 및 그의 용도
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
US7183376B2 (en) * 2000-06-23 2007-02-27 Maxygen, Inc. Variant B7 co-stimulatory molecules

Also Published As

Publication number Publication date
CZ20021760A3 (cs) 2003-05-14
IL149701A0 (en) 2002-11-10
HUP0201737A2 (hu) 2003-02-28
CN1404876A (zh) 2003-03-26
ZA200204020B (en) 2003-11-21
KR100531707B1 (ko) 2005-11-30
CA2382443A1 (en) 2002-11-23
KR20020090873A (ko) 2002-12-05
PL354112A1 (en) 2002-12-02
EP1262193A1 (en) 2002-12-04
SK7242002A3 (en) 2003-07-01
US20030086930A1 (en) 2003-05-08
MY136095A (en) 2008-08-29
HU0201737D0 (en:Method) 2002-07-29
JP2002371013A (ja) 2002-12-26

Similar Documents

Publication Publication Date Title
KR100531707B1 (ko) 항-ctla-4 항체의 용도
CN1328571B (zh) 抗ctla-4的人单克隆抗体
TW200829271A (en) Uses of anti-CTLA-4 antibodies
US6682736B1 (en) Human monoclonal antibodies to CTLA-4
KR102551269B1 (ko) 저-점도 항원 결합 단백질 및 이의 제조 방법
CA2537876C (en) Antibodies to m-csf
US20040228861A1 (en) Human monoclonal antibodies to CTLA-4
KR20070104673A (ko) 암의 치료를 위한 항-ctla4 항체와 인돌리논병용요법
KR20070067702A (ko) 유방암을 치료하기 위한 ctla-4 항체와 아로마타제억제제 병용 요법
KR20070108259A (ko) Ctla-4 항체와 호르몬 요법에 의한 전립선암의 치료법
CN101268101A (zh) 用于癌症治疗的抗-CTLA-4抗体和含有CpG基序的合成寡脱氧核苷酸联合治疗
TW200535144A (en) Antibodies to madcam
KR20050059263A (ko) 에리트로포이에틴 수용체 결합 항체
KR20200109339A (ko) Tim3에 대한 항체를 사용하여 암을 치료하는 방법
HK1103020A (en) Uses of anti-ctla-4 antibodies
HK1050849A (en) Use of anti-ctla-4 antibodies